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Anti-EGFR targeted therapy is a potent strategy in the treatment of metastatic colorectal cancer (mCRC) but activating mutations
in the KRAS gene are associated with poor response to this treatment. Therefore, KRAS mutation analysis is employed in the
selection of patients for EGFR-targeted therapy and various studies have shown a high concordance between the mutation status
in primary CRC and corresponding metastases. However, although development of therapy related resistance occurs also in the
context of novel drugs such as tyrosine kinase-inhibitors the effect of the anti-EGFR treatment on the KRAS/BRAF mutation status
itself in recurrent mCRC has not yet been clarified. Therefore, we analyzed 21 mCRCs before/after anti-EGFR therapy and found a
pre-/posttherapeutic concordance of the KRAS/BRAF mutation status in 20 of the 21 cases examined. In the one discordant case,
further analyses revealed that a tumor mosaicism or multiple primary tumors were present, indicating that anti-EGFR therapy
has no influence on KRAS/BRAF mutation status in mCRC. Moreover, as the preselection of patients with a KRASwt genotype for
anti-EGFR therapy has become a standard procedure, sample sets such ours might be the basis for future studies addressing the
identification of potential anti-EGFR therapy induced genetic alterations apart from KRAS/BRAF mutations.
Copyright © 2009 S. Gattenlo¨hner et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Introduction
Colorectal carcinoma (CRC) is one of the most common
forms of malignant neoplasia and frequently takes a fatal
course following metastasis [1]. CRC is a multipathway
disease involving dysregulatory phenomena in a number
of signal transduction pathways [2]. The epidermal growth
factor receptor (EGFR), a tyrosine kinase receptor belong-
ing to the ErbB family, is overexpressed in 25%–80% of
CRCs and has been found to play a major role in the
pathogenesis of CRC by inducing downstream signaling
pathways such as the phosphatidylinositol-3-kinase/Akt and
Ras/Raf/mitogen-activated protein kinase (MAPK) path-
ways, which are crucial in the regulation of cell growth,
proliferation, apoptosis, invasion, migration, and angio-
genesis [3]. Consequently, antibodies targeting EGFR, such
as cetuximab and panitumumab, have been examined for
therapeutic efficacy in CRC patients [4]. Although it was
determined that combination therapy of irinotecan and
cetuximab is significantly more successful in the treatment
of metastatic CRC (mCRC) than irinotecan alone, the overall
therapeutic response rate to combined cetuximab therapy is
less than 30%, suggesting that there are escape mechanisms
present in many cases of CRC [5, 6]. Among others, mutation
of the genes encoding the Kirsten rat sarcoma viral oncogene
homologue (KRAS) and the V-raf murine sarcoma viral
oncogene homolog B1 (BRAF) wes established as two of
these mechanisms and preselection of CRC patients with a
KRASwt genotype have been shown to increase the therapeu-
tic efficacy of anti-EGFR therapy [7, 8]. Therefore, clinical
trials involving anti-EGFR therapy are now commonly con-
ducted with patients preselected for KRASwt mutation status
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Table 1: Primer data for sequencing and allele specific PCR for
KRAS exon 2 and BRAF exon 15 mutation analysis.
KRAS
d1
5′-GAG TTT GTA TTA AAA GGT ACT
GG-3′
d2
5′-TAC TGG TGG AGT ATT TGA TAG
TG-3′
r1 + r2 5′-CTG TAT CAA AGA ATG GTC CTG-3′
BRAF
d 5′-TGC TTG CTC TGA TAG GAA AAT-3′
r 5′-CTG ATG GGA CCC ACT CCA T-3′
[9, 10]. To ensure that therapy targeting EGFR is effective in
primary CRC as well as in corresponding metastases, various
studies have examined the concordance or discordance of
KRAS and BRAF mutation status in primary CRC and
corresponding metastases. Although the results of these
studies appear contradictory in part, the majority of authors
report high rates of concordance between the mutation status
of KRAS in primary tumors and corresponding metastases
[4, 9, 11–16]. In a study published recently by our group,
KRAS mutation status was monitored in the primary tumors
and corresponding metastases of 106 cases of mCRC [17].
Here, we found concordance in the mutation status of KRAS
in 105 of 106 cases (Figure 1) and were able to show that the
only case of discordance was due to a tumor mosaic or the
coexistence of multiple primary tumors (Figure 2), a fact that
could help in explaining the partially contradicting results
reported in the past [13, 17]. Moreover, in analogy to other
types of cancer [18–20], therapy-related resistance based on
a treatment-induced shift in KRAS and/or BRAF mutation
status could also play a role in explaining the low therapeutic
efficacy of anti-EGFR therapy in mCRC by rendering tumor
cells initially responsive to anti-EGFR mAbs resistant to this
therapeutic regimen [9].
2. Materials and Methods
49 individual specimens of 21 metastatic CRCs and cor-
responding metastases collected before and after combined
therapy with cetuximab were examined using CGH, certified
PCR/DNA sequencing protocols (KRAS exon 2, Gl12/13;
BRAF exon 15, V600E) as well as allele-specific PCR [8].
The majority of samples analyzed in this approach
derived from the sample pool of 106 mCRC with 270 syn-
/metachronic metastases used in our earlier study on the
concordance of KRAS mutation status in primary CRC and
corresponding metastases [17]. Biopsy sets were collected
before and after combined cetuximab therapy, whereby the
samples collected before therapy were taken from primary
CRCs and/or liver metastases, while those gathered after
therapy were from metastases in different locations, predom-
inantly the liver (Table 2). Each CRC studied was clinically
documented as a single primary malignant tumor in the
colon/rectum and all metastases were identified as such
by a characteristic “CRC-like” immunohistochemical profile
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Figure 1: Overview of patient data from an investigation of the con-
cordance of 106 primary CRCs and 270 corresponding metastases
syn-/metachronic metastases. Each line represents an individual
patient with primary CRC and metastatic manifestations. Red
bars demonstrate KRAS mutation positive CRCs (n = 42) with
corresponding lymph node metastases (n = 26), liver metastases (n
= 40), lung metastases (n = 22), and other sites (n = 18) including
bone marrow (n = 6), soft tissue (n = 5), and peritoneum (n =
7). Green bars show KRAS mutation negative CRCs (n = 63) with
corresponding lymph node metastases (n = 43), liver metastases
(n = 61), lung metastases (n = 28), and other sites (OS) (n =
32) including bone marrow (n = 10), soft tissue (n = 13) and
peritoneum (n = 9). In case #43 a heterogeneously differentiated
primary CRC (see also Figure 2) showed a KRAS mosaicism (red
and green bars in pCRC) with detection of KRAS mutation G12V
in other sites (OS, undifferentiated soft tissue und peritoneal
metastases (red bars)) but not in moderately differentiated lymph
node and liver metastases (LN and LI, green bars). LN: lymph node;
LI: liver; LU: lung; OS: other sites.
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(cytokeratin 20 positive, cytokeratin 7 negative). Following
pathohistological characterization, tumor cells were enriched
to >90% from 4–6 10 μm slices using microdissection. Two
independent samples from each specimen were incubated
overnight in lysis buffer containing proteinase K at 56◦C
and DNA was subsequently extracted by column affinity
chromatography (Qiagen DNA Minikit, Cat No 51306).
CGH was performed as previously described [17].
Briefly, DNA was labeled by nick translation with biotin-
16-dUTP (Roche Diagnostics, Mannheim, Germany). After
inactivation of DNase I (Roche Diagnostics, Mannheim,
Germany) equal amounts (1 μg) of tumor and refer-
ence DNA (DIG-labeled DNA from placental tissue of a
healthy newborn) were cohybridized on metaphase slides
(Vysis, Downers Grove, IL). Signals were visualized with
a Zeiss Axiophot fluorescence microscope and analyzed
with the ISIS digital image analysis system (MetaSystems,
Altlussheim, Germany).
KRAS and BRAF mutation analyses were performed on
two independent samples from all primary tumors/
metastases using protocols described previously [8]. Briefly,
DNA was amplified using Taq DNA Polymerase (Invitrogen
Cat. No. 10342-020) and allele specific primers (Eurofins, see
Table 1). Amplificates were visualized in 2% agarose gels and
purified from the gels using column affinity chromatography
(QIAquick Gel Extraction Kit, Qiagen Cat. No. 28704).
Sequencing PCR was performed using PCR primers (see
Table 1) and ABI BigDye Terminator v3.1 Cycle Sequencing
RR-100 (ABI Heidelberg, Germany) as described [17].
3. Results
In the first part of our study we analyzed 106 metastatic CRCs
with at least 2 multifocal and syn-/metachronic metastases
(n = 270) using PCR/DNA sequencing protocols certified
by the German Society for Pathology (exon 2, Glycin12 and
Glycin13) as well as allele-specific PCR approaches. As shown
in Figure 1, we observed concordance of the KRAS mutation
status between primary CRCs and all corresponding metas-
tases in 105 of 106 patients. However in one case (Figure 1
#43) of a KRAS mutation G12V positive moderately dif-
ferentiated and undifferentiated primary CRC (Figure 2(a)),
the mutation was detectable in soft tissue and peritoneal
metastases with infiltrates from the undifferentiated tumour
fraction (Figures 2(b) and 2(c)), but not in moderately
differentiated lymph node and liver metastases (Figures
2(e) and 2(f)). Microdissected subfractions of the primary
heterogeneous CRC showed a corresponding mutational
mosaicism with detection of KRAS mutation G12V only in
the undifferentiated tumour areas (Figures 2(d) and 2(g)).
In the second part of the study we addressed the
question, whether combined cetuximab therapy might influ-
ence the KRAS/BRAF mutation status in mCRC. Therefore
16 patients from the described sample pool (Figure 1) as
well as 5 novel patients (including case #4, see Table 2)
suffering from mCRC were analyzed for the KRAS/BRAF
mutation status using the above mentioned molecular and
immunohistochemical techniques.
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Figure 2: Morphological changes and results of KRAS mutation
analyses in case #43 of a heterogeneously differentiated CRC with
mosaicism for KRAS mutation G12D. In Figure 2(a) moderately
(right half) and undifferentiated (left half) tumor areas reveal
positive detection of KRAS mutation G12V (inset). In contrast,
only in soft tissue (b) and peritoneal (c) metastases harbouring
exclusively undifferentiated tumor infiltrates an identical KRAS
mutation was detectable ((b) and (c) insets), whereas in lymph
node (e) and liver (f) metastases with moderately differentiated
tumor infiltrates only, no KRAS mutation was found ((e) and
(f) insets). After microdissection of undifferentiated (d) and
moderately differentiated (g) areas from primary CRC the KRAS
mutation G12V was only detectable in the undifferentiated fraction
((d), inset). Images were produced with a B × 50 microscope
(Olympus, Hamburg, Germany) and a DP50 digital camera with
DP-Soft 5.0 software (Olympus, Hamburg, Germany).
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Table 2: Overview of the clinical patient data. 20 of 21 patients show concordance of the KRAS (exon 2, Gly 12/13) and BRAF (exon 15,
V600E) mutation status between samples of primary CRCs and/or corresponding metastases before and after combined cetuximab therapy.
In one case (#4), the primary CRC had a mutated KRAS gene (Gly12Asp), while the liver metastasis biopsied after combined cetuximab
therapy showed a KRASwt genotype. BRAF mutation status in this case was concordant between the samples gathered before and after
anti-EGFR therapy.
Case no. Sex/Age
Date and localisation of
tumor manifestaion
KRAS
Gly12/13
(exon2)
BRAF V600E
(exon15)
Anti-EGFR therapy
1 M/51 y
09/05 primary CRC Gly12Val WT
01/07–04/07
Folfiri/Cetuximab (PD)
11/07 small bowel
metastasis
Gly12Val WT dead 05/08
2 M/71 y
11/02 soft tissue Gly12Cys WT
09/04–08/05
Folfiri/Cetuximab (PR)
03/06 mesocolon
transversum metastasis
Gly12Cys WT
3 M/46 y
03/07 primary CRC WT WT
08/07–06/08
Folfiri/Cetuximab (PR)
02/09 peritoneal carcinosis WT WT
4 M/68 y
11/06 primary CRC Gly12Asp WT
04/07–02/08
Fufox/Cetuximab(PR)
03/08 liver metastasis WT WT
5 F/56 y
07/08 primary CRC Gly12Asp WT
07/08–09/08
Fufox/Cetuximab (PD)
12/08 peritoneal carcinosis Gly12Asp WT dead 12/08
6 M/71 y
12/05 primary CRC Gly12Val WT
01/06–07/06
Folfiri/Cetuximab (PD)
12/06 liver metastasis Gly12Val WT dead 04/08
7 F/58 y
01/08 primary CRC WT WT
04/08–07/08
Folfiri/Cetuximab (PD)
07/08 peritoneal carcinosis WT WT dead 07/08
8 F/44 y
11/07 primary CRC WT WT
05/08–03/09
Folfox/Cetuximab (PR)
12/08 peritoneal carcinosis WT WT
9 F/66 y
02/04 primary CRC Gly12Ser WT
07/06–09/06
Folfox/Cetuximab (PR)
11/05 + 04/06 liver
metastasis
Gly12Ser WT
07/06–09/06
Folfox/Cetuximab (PD)
11/06 lung metastasis Gly12Ser WT
09/06-11/06
Folfiri/Avastin (PD)
10 M/77 y
11/05 primary CRC Gly13Asp WT
12/05–09/06 Folfox +
Cetuximab (PD)
07/06 lymph node Gly13Asp WT
10/06–02/07 Folfiri +
Avastin (PD) dead 05/07
11 M/63 y
05/07primary CRC WT WT
05/07–07/08
Folfiri/Cetuximab (PR)
01/08 liver metastasis WT WT 10/08–05/09 Folfox (PR)
06/09 liver metastasis WT WT
12 M/67 y
07/07 liver metastasis WT WT
08/07–04/08
Folfox/Cetuximab (PR)
01/08 liver metastasis WT WT
13 M/59 y
09/07 primary CRC WT WT
10/07 liver metastasis WT WT
11/07–03/08
Folfiri/Cetuximab (PR)
05/08 liver metastasis WT WT
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Table 2: Continued.
Case no. Sex/Age
Date and localisation of
tumor manifestaion
KRAS
Gly12/13
(exon2)
BRAF V600E
(exon15)
Anti-EGFR therapy
14 M/61 y
07/02 primary CRC WT WT
10/07–07/08
Folfox/Cetuximab (PR)
05/04 liver metastasis WT WT
07/08 peritoneal carcinosis WT WT Since 12/08 Folfox (PR)
15 F/68 y
09/05 primary CRC WT V600E 10/05–02/06 Folfox (PD)
05/06 soft tissue WT V600E
03/06–08/06
Folfiri/Cetuximab (PR)
01/07 soft tissue WT V600E
01/07–05/07
Cetuximab/Irinotecon
(PD)
dead 06/07
16 M/75 y
07/00 primary CRC Gly12Asp WT
07/03 lung metastasis Gly12Asp WT 08/03–07/04 Folfox (PD)
08/03 liver metastasis 08/04–08/05 Folfiri (PD)
08/05 liver metastasis Gly12Asp WT
08/05–04/06
Folfiri/Cetuximab (PD)
04/06–02/07
Cetuximab+CPT-
11(PD)
02/07–04/07
Panitumumab (PD)
04/07 ascites Gly12Asp WT dead 05/07
17 M/69 y
06/02 primary CRC Gly13Asp WT
06/02–09/02 Folfox (PR)
06/03–12/03 Folfox (PR)
07/04–01/06 Folfiri (PD)
03/06–05/06 Cetuximab
+ CPT-11 (PD)
09/06–02/07 Folfox (PD)
07/07 mesocolon metastasis Gly13Asp WT dead 09/07
18 M/75 y
01/04 primary CRC Gly12Asp WT
06/07–10/07
Capecitabine/Cetximab
(PD)
01/08 peritoneal carcinosis Gly12Asp WT dead 03/08
19 F/61 y
07/08 primary CRC WT WT
07/08–03/09
Folfiri/Cetuximab (PR)
05/09 liver metastasis WT WT
20 M/56 y
05/08 primary CRC WT WT
06/08-12/08
Folfox/Cetuximab (PR)
06/09 lung metastasis WT WT
21 M/72 y
09/08 primary CRC WT WT
10/08-02/09
Folfiri/Cetuximab (PR)
01/09 liver metastasis WT WT
Response evaluation (according to RECIST criteria): PD: progressive disease; SD: stable disease; PR: partial remission; CR: complete remission.
We hereby observed a concordance in the KRAS and
BRAF mutation status between samples from primary CRCs
and/or corresponding metastases before and after combined
cetuximab therapy in 20 of 21 patients (Table 2). The
timespan between first and last sampling ranged between
4 and 81 months (average 25,8 months) and the patients
involved in the study received 1 to 5 rounds of therapy
(average 1,8 rounds) during this period.
6 Journal of Oncology
(a) (b)
G A T G G C
96 97 98 99 100 101
(c)
G G T G G C
91 92 93 94 95 96
(d)
4(8) 6(12) 20(12)
20
20
4
6
6
(e)
4(10) 6(12) 20(12)
+ 20
+ 20
− 4
− 4
− 6q
− 6q
(f)
Figure 3: Further analysis of biopsies from the patient with a discordant KRAS mutation status before and after anti-EGFR therapy (#4,
see Table 2) showing varying morphology between primary CRC with papillary tissue organization (a) and liver metastasis with tubular
tissue organization (b). KRAS mutations analysis of corresponding specimens demonstrate detection of KRAS mutation exon 2 Gly12D (c)
in primary CRC whereas an unmutated KRAS status in the liver metastasis was detectable (d). In fluorescence scan and data analysis of CGH
only in the liver metastasis biopsied after treatment (f) but not in the primary CRC (e) a decrease in fluorescence of chromosomes 4 and 6
and an increase of chromosome 20 (arrows) could be seen.
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In the one case of discordance between KRAS mutation
status before and after combined cetuximab therapy (case
#4), a mutated KRAS gene (Exon 2 G12D) was found in the
primary CRC, while no KRAS mutation was observed in a
liver metastasis sample obtained after combined cetuximab
therapy (Table 2). Further analysis of the biopsy samples
in this patient revealed that the primary CRC sampled
before therapy and the liver metastasis biopsied after ther-
apy showed differences not only in their KRAS mutation
status but also in morphology and overall genetic compo-
sition (Figure 3). While the primary tumor was predom-
inantly organized in a papillary fashion (Figure 3(a)), the
liver metastasis displayed a distinctly tubular organization
(Figure 3(b)). As mentioned above, microdissected samples
gathered from each of these specimens showed distinct
genetic sequences in exon 2 of the KRAS gene. While a
mutated KRAS gene (Exon 2 G12D) was observed in the
primary CRC (Figure 3(c)), a KRASwt genotype was found
in the liver metastasis (Figure 3(d)). Moreover, comparative
genomic hybridization performed on the samples revealed
that each of these displayed different genetic alterations. In
comparison to the primary CRC (Figure 3(e)), samples from
the liver metastasis showed sequence losses in chromosomes
4 and 6, while gains were observed in chromosome 20
(Figure 3(f)).
4. Discussion
Development of therapy-related resistance is a frequent
phenomenon in cancer and also occurs in the context of
novel drugs such as monoclonal antibodies and tyrosine
kinase inhibitors. In gastrointestinal stromal tumors (GISTs),
the most common mesenchymal neoplasm of the gastroin-
testinal tract, mechanisms of resistance to imatinib mesylate
(GleevecR) include both de novo and, more frequently,
acquired resistance, which may occur after several months
of drug administration and most often is based upon an
acquired second mutation in the c-kit and PDGFRα genes
[18, 19]. In B-cell lymphoma, resistance to the chimeric
anti-CD20 monoclonal antibody rituximab, the first mon-
oclonal antibody to have been registered for the treatment
of B-cell lymphomas, is suggested to be due to reduced
expression of CD20, the failure of rituximab to trigger
the cells leading to inhibition of antibody-dependent and
complement-dependent cell toxicity (ADCC and CDC), as
well as hyperactivation of antiapoptotic signaling pathways
such as p38 MAP kinase, NF-kappaB, ERK1, and AKT [20].
In the first part of our study we analyzed a well-
documented cohort of 106 metastatic CRCs with 270 syn-
/metachronic metastases concerning the KRAS mutation
status showing an overall concordance of the KRAS mutation
status in primary CRCs and metastases in 99% of the cases
examined that stands in good accordance to previous reports
[21]. However, apart from potentially coexisting secondary
malignancies, the KRAS mutation mosaicism found in one
heterogeneously differentiated CRC (#43, Figures 1 and 2)
may explain the discordant results concerning this trait
in primary CRCs and metastases reported previously [12,
13, 22] and underlines the necessity for diligent clinical
and histological characterization of any atypical tumour
manifestation in mCRC to prevent misleading results with
negative impact on anti-EGFR targeted therapies.
The second and major part of our study was to investigate
whether therapy-related resistance due to acquired second
KRAS/BRAF mutations also occurs in metastatic colorectal
cancer after anti-EGFR therapy. Therefore we analyzed
49 individual specimens from 21 mCRC collected before
and after combined cetuximab therapy. Of the 21 patients
examined in this study, 20 showed concordance between the
KRAS mutation status before and after combined cetuximab
therapy, while the rate of concordance for BRAF was 100%.
In one patient (case #4, Table 2) that did not derive from
the above mentioned sample pool of 106 mCRC, the KRAS
mutation status was discordant between the samples col-
lected before and after cetuximab therapy, but due to further
analysis of these samples with clearly different morphological
and genomic features (Figure 3) it might be suggested that
populations of carcinoma cells heterogeneous with respect
to wild-type and mutant KRAS were probably present in the
primary carcinoma, but the metastatic clone derived from a
KRAS negative population, as reported previously [22, 23].
The results of this study provide first evidence that
secondary KRAS/BRAF mutations do not play a major
role in therapy-related resistance to anti-EGFR antibody
treatment in mCRC, although it cannot be excluded that
KRAS/BRAF mutations beyond Glycin12/13 KRAS exon2
and V600E BRAF exon15 as well as secondary resistance
due to combinational chemotherapies (as in most patients
investigated) are responsible for therapy-related resistance
in mCRC. Moreover, as the preselection of patients with
a KRASwt genotype for cetuximab therapy has become a
standard procedure, sample sets such as the one used in
this study will have to be conserved carefully for use in
future studies particularly with respect to analyses addressing
the identification of anti-EGFR therapy-induced genetic
alterations apart from KRAS/BRAF mutations.
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